• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲氨蝶呤在越南银屑病关节炎患者中的有效性、安全性及耐受性

Effectiveness, Safety and Tolerance of Methotrexate in Vietnamese Psoriatic Arthritis Patients.

作者信息

Thi Van Bui, Minh Vinh Ngo, Ngoc Anh Tran, Dang Quyet Tran, Ngoc Diep Le, Van Em Dang, Van Thuong Nguyen, Minh Phuong Pham Thi, Thu Hien Do Thi, Huu Nghi Dinh, Huyen My Le, Hau Khang Tran, Gandolfi Marco, Satolli Francesca, Feliciani Claudio, Tirant Michael, Vojvodic Aleksandra, Lotti Torello

机构信息

Military Central Hospital, Hanoi City, Vietnam.

Pham Ngoc Thach University of Medicine, HCMC, Vietnam.

出版信息

Open Access Maced J Med Sci. 2019 Jan 27;7(2):250-252. doi: 10.3889/oamjms.2019.063. eCollection 2019 Jan 30.

DOI:10.3889/oamjms.2019.063
PMID:30745972
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6364709/
Abstract

AIM

To access the effectiveness, safety and tolerance of methotrexate (MTX) in psoriatic arthritis (PsA) treatment.

METHODS

We recruit 37 patients, admitted at HCMC Hospital of Dermato-Venereology from 1/2016 to 3/2017, with MTX dosage ranging from 10 mg to 15 mg per week.

RESULTS

Skin lesion response after 12 weeks improved PASI 50: 40.5%, PASI 75: 24.3%. Disease activity score decreased after 12 weeks with ∆DAS28 = -1.43 + 0.79, 37.8% PsA achieved complete remission. Nausea and vomiting were 8.1%. These symptoms were mild and transient. We did not stop MTX usage. The rate of elevating SGPT 2-3 times as much as the upper limit of the normal range was 2.7%.

CONCLUSION

We finally demonstrated that the rate of treatment response in Vietnam is the same as demonstrated by foreign authors in other countries.

摘要

目的

评估甲氨蝶呤(MTX)治疗银屑病关节炎(PsA)的有效性、安全性和耐受性。

方法

我们招募了37例患者,于2016年1月至2017年3月在胡志明市皮肤病与性病医院入院,MTX剂量为每周10毫克至15毫克。

结果

12周后皮肤病变反应改善,PASI 50改善率为40.5%,PASI 75改善率为24.3%。12周后疾病活动评分下降,∆DAS28 = -1.43 + 0.79,37.8%的PsA患者实现完全缓解。恶心和呕吐发生率为8.1%。这些症状轻微且短暂。我们未停止MTX使用。谷丙转氨酶升高至正常范围上限2至3倍的发生率为2.7%。

结论

我们最终证明越南的治疗反应率与其他国家的外国作者所证明的相同。

相似文献

1
Effectiveness, Safety and Tolerance of Methotrexate in Vietnamese Psoriatic Arthritis Patients.甲氨蝶呤在越南银屑病关节炎患者中的有效性、安全性及耐受性
Open Access Maced J Med Sci. 2019 Jan 27;7(2):250-252. doi: 10.3889/oamjms.2019.063. eCollection 2019 Jan 30.
2
Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate.早期使用 TNF 抑制剂治疗银屑病关节炎以达到缓解:戈利木单抗联合甲氨蝶呤与安慰剂联合甲氨蝶呤的双盲、随机、安慰剂对照试验。
Ann Rheum Dis. 2019 May;78(5):610-616. doi: 10.1136/annrheumdis-2018-214746. Epub 2019 Feb 26.
3
Methotrexate achieves major cDAPSA response, and improvement in dactylitis and functional status in psoriatic arthritis.甲氨蝶呤可实现主要 cDAPSA 缓解,并改善银屑病关节炎的关节炎和功能状态。
Rheumatology (Oxford). 2019 May 1;58(5):869-873. doi: 10.1093/rheumatology/key369.
4
Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.阿达木单抗用于银屑病关节炎的长期治疗:来自阿达木单抗治疗银屑病关节炎有效性试验的48周数据。
Arthritis Rheum. 2007 Feb;56(2):476-88. doi: 10.1002/art.22379.
5
Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.依那西普和英夫利昔单抗治疗银屑病关节炎:系统评价与经济学评估
Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. doi: 10.3310/hta10310.
6
Results of one-year treat-to-target strategy in early psoriatic arthritis: data of an open-label REMARCA study.早期银屑病关节炎一年达标治疗策略的结果:开放标签REMARCA研究的数据
Ter Arkh. 2018 May 11;90(5):22-29. doi: 10.26442/terarkh201890522-29.
7
Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial.在早期银屑病关节炎中,TNF-α 抑制剂和甲氨蝶呤诱导治疗 22 周后,用甲氨蝶呤单药维持缓解:一项随机安慰剂对照试验的开放性扩展。
Arthritis Res Ther. 2019 Sep 14;21(1):208. doi: 10.1186/s13075-019-1998-4.
8
Addition or removal of concomitant methotrexate alters adalimumab effectiveness in rheumatoid arthritis but not psoriatic arthritis.在类风湿关节炎中,同时添加或去除甲氨蝶呤会改变阿达木单抗的疗效,但在银屑病关节炎中则不然。
Scand J Rheumatol. 2019 Sep;48(5):375-382. doi: 10.1080/03009742.2019.1600717. Epub 2019 Jul 16.
9
Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis.比较甲氨蝶呤治疗银屑病关节炎与类风湿关节炎患者的疗效和保留率。
Ann Rheum Dis. 2010 Apr;69(4):671-6. doi: 10.1136/ard.2009.113308. Epub 2009 Sep 9.
10
Attainment of Minimal Disease Activity Using Methotrexate in Psoriatic Arthritis.使用甲氨蝶呤实现银屑病关节炎的最小疾病活动度
J Rheumatol. 2016 Sep;43(9):1718-23. doi: 10.3899/jrheum.160111. Epub 2016 Jul 15.

本文引用的文献

1
Factors associated with successful switching between biologic therapies for the treatment of psoriasis in daily dermatological real-life practice: The Resoswitch study.在日常皮肤科实际临床实践中,与银屑病生物治疗成功转换相关的因素:Resoswitch研究
Dermatol Ther. 2019 Mar;32(2):e12789. doi: 10.1111/dth.12789. Epub 2019 Jan 17.
2
Adjuvant treatment of chronic plaque psoriasis in adults by a herbal combination: Open German trial and review of the literature.一种草药组合对成人慢性斑块状银屑病的辅助治疗:德国开放性试验及文献综述
Dermatol Ther. 2020 Jul;33(4):e12624. doi: 10.1111/dth.12624. Epub 2018 Sep 2.
3
Complementary and integrative therapies for psoriasis: Looking forward.银屑病的补充和综合疗法:展望未来。
Dermatol Ther. 2018 Sep;31(5):e12627. doi: 10.1111/dth.12627. Epub 2018 Aug 22.
4
Is There a Place for Local Natural Treatment of Psoriasis?银屑病的局部自然疗法是否有一席之地?
Open Access Maced J Med Sci. 2018 May 18;6(5):839-842. doi: 10.3889/oamjms.2018.106. eCollection 2018 May 20.
5
Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis Study.甲氨蝶呤在银屑病关节炎严格控制研究中的疗效
J Rheumatol. 2016 Feb;43(2):356-61. doi: 10.3899/jrheum.150614. Epub 2015 Dec 15.
6
European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.欧洲抗风湿病联盟(EULAR)药物治疗银屑病关节炎管理建议:2015 年更新。
Ann Rheum Dis. 2016 Mar;75(3):499-510. doi: 10.1136/annrheumdis-2015-208337. Epub 2015 Dec 7.
7
The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study.甲氨蝶呤联合治疗在 TNF 抑制剂治疗银屑病关节炎患者中的作用:来自 NOR-DMARD 研究中纳入的 440 例患者的结果。
Ann Rheum Dis. 2014 Jan;73(1):132-7. doi: 10.1136/annrheumdis-2012-202347. Epub 2013 Jan 3.
8
A randomized placebo-controlled trial of methotrexate in psoriatic arthritis.一项关于甲氨蝶呤治疗银屑病关节炎的随机安慰剂对照试验。
Rheumatology (Oxford). 2012 Aug;51(8):1368-77. doi: 10.1093/rheumatology/kes001. Epub 2012 Feb 17.
9
Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis.德国银屑病关节炎的流行病学与临床特征:一项对1511例斑块状银屑病患者的前瞻性跨学科流行病学研究
Br J Dermatol. 2009 May;160(5):1040-7. doi: 10.1111/j.1365-2133.2008.09023.x. Epub 2009 Feb 4.
10
Toxicity of methotrexate treatment in psoriasis and psoriatic arthritis--short- and long-term toxicity in 104 patients.甲氨蝶呤治疗银屑病和银屑病关节炎的毒性——104例患者的短期和长期毒性
Clin Rheumatol. 2001;20(6):406-10. doi: 10.1007/s100670170004.